Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amir Sharabi

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|May 6, 2016
Editorial: Molecules Balancing Immunological Surveillance against Cancer and Autoimmune DiseasesAmir Sharabi
Current Rheumatology Reports|July 2, 2021
Updates on Clinical Trials in Systemic Lupus ErythematosusAmir Sharabi
Autoimmunity Reviews|July 28, 2010
A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosusEdna Mozes, Amir Sharabi
Immunotherapy|July 20, 2010
Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseasesAmir Sharabi, Edna Mozes
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2008
The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cellsAmir Sharabi, Edna Mozes
Arthritis Research & Therapy|August 7, 2010
Bcl-xL affects the development of functional CD4 TregsAmir Sharabi, Edna Mozes
Nature Reviews. Rheumatology|January 18, 2020
T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapyAmir Sharabi, George C Tsokos
Bone Marrow Research|November 3, 2011
Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapyAmir Sharabi, Nechama Haran-Ghera
Advances in Cancer Research|April 20, 2010
Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapyAmir Sharabi, Nechama Haran Ghera
Clinical Immunology (Orlando, Fla.)|November 11, 2021
Adult-onset Still's disease following mRNA COVID-19 vaccinationAmir Sharabi, Shachaf Shiber, Yair Molad
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|May 6, 2016
Editorial: Molecules Balancing Immunological Surveillance against Cancer and Autoimmune DiseasesAmir Sharabi
Current Rheumatology Reports|July 2, 2021
Updates on Clinical Trials in Systemic Lupus ErythematosusAmir Sharabi
Autoimmunity Reviews|July 28, 2010
A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosusEdna Mozes, Amir Sharabi
Immunotherapy|July 20, 2010
Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseasesAmir Sharabi, Edna Mozes
Journal of Immunology (Baltimore, Md. : 1950)|August 21, 2008
The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cellsAmir Sharabi, Edna Mozes
Arthritis Research & Therapy|August 7, 2010
Bcl-xL affects the development of functional CD4 TregsAmir Sharabi, Edna Mozes
Nature Reviews. Rheumatology|January 18, 2020
T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapyAmir Sharabi, George C Tsokos
Bone Marrow Research|November 3, 2011
Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapyAmir Sharabi, Nechama Haran-Ghera
Advances in Cancer Research|April 20, 2010
Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapyAmir Sharabi, Nechama Haran Ghera
Clinical Immunology (Orlando, Fla.)|November 11, 2021
Adult-onset Still's disease following mRNA COVID-19 vaccinationAmir Sharabi, Shachaf Shiber, Yair Molad
Pageof 5